Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multicenter Phase I Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-7058 Monotherapy in Patients With Advanced Solid Tumour With KRAS G12C Mutation

NCT06383871 is registered in ClinicalTrials.gov with Shandong Suncadia Medicine Co., Ltd. as lead sponsor.

NCT NCT06383871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06383871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multicenter Phase I Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-7058 Monotherapy in Patients With Advanced Solid Tumour With KRAS G12C Mutation
Lead sponsor
Shandong Suncadia Medicine Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
June 6, 2024
Completion date
June 30, 2026
Enrollment
233 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant tumour